Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination

Karim Dorgham, Valérie Abadie, Mutsunori Iga, Oliver Hartley, Guy Gorochov, Behazine Combadière

研究成果: Contribution to journalArticle査読

13 被引用数 (Scopus)

抄録

Chemokine receptors are promising targets for enhancing T-cell immunity and anti-cancer therapy. CCL5 is a potential adjuvant for DNA vaccination. We postulated that CCR5 superagonists could be even more effective. A CCR5 superagonist derived from natural CCL5 by directed in vitro evolution, namely 1P7, is used as a DNA vaccine adjuvant and expressed as fused chemokine-Ig (1P7-Ig). We show that OVA + 1P7-Ig DNA co-inoculation induced higher frequencies of OVA-specific CD8 lymphocytes than OVA + CCL5-Ig or controls and gave an even better protection against tumor growth in a CCR5-dependant manner. Our results indicate that CCR5-superagonists may provide potent adjuvants for vaccines.

本文言語英語
ページ(範囲)3252-3260
ページ数9
ジャーナルVaccine
26
26
DOI
出版ステータス出版済み - 6 19 2008

All Science Journal Classification (ASJC) codes

  • 分子医療
  • 免疫学および微生物学(全般)
  • 獣医学(全般)
  • 公衆衛生学、環境および労働衛生
  • 感染症

フィンガープリント

「Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル